Faisal Khurshid
Stock Analyst at Leerink Partners
(4.61)
# 214
Out of 5,152 analysts
30
Total ratings
60.87%
Success rate
41.41%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $70 → $118 | $83.52 | +41.28% | 3 | Dec 9, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $13 → $16 | $13.08 | +22.32% | 2 | Nov 20, 2025 | |
| ABCL AbCellera Biologics | Downgrades: Market Perform | $4 | $3.59 | +11.42% | 2 | Nov 7, 2025 | |
| GLPG Galapagos NV | Upgrades: Outperform | $29 → $40 | $33.38 | +19.83% | 2 | Oct 21, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Outperform | $20 | $13.81 | +44.82% | 1 | Sep 25, 2025 | |
| ATYR aTyr Pharma | Downgrades: Market Perform | $1 | $0.90 | +10.83% | 2 | Sep 15, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $73 | $91.41 | -20.14% | 1 | Sep 12, 2025 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $5.10 | -60.78% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $91.46 | +11.52% | 2 | Jul 10, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $3.62 | -72.38% | 2 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $40.59 | +10.86% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $16 | $15.22 | +5.12% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $33 → $2 | $1.29 | +55.04% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $75.60 | +5.82% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $6.76 | +121.89% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $17.19 | +161.78% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.42 | +392.96% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $2.83 | +182.69% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $1.11 | +350.45% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $2.78 | +295.68% | 1 | Mar 21, 2023 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $70 → $118
Current: $83.52
Upside: +41.28%
Trevi Therapeutics
Nov 20, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $13.08
Upside: +22.32%
AbCellera Biologics
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $3.59
Upside: +11.42%
Galapagos NV
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $33.38
Upside: +19.83%
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $13.81
Upside: +44.82%
aTyr Pharma
Sep 15, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.90
Upside: +10.83%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $91.41
Upside: -20.14%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $5.10
Upside: -60.78%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $91.46
Upside: +11.52%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $3.62
Upside: -72.38%
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $40.59
Upside: +10.86%
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $15.22
Upside: +5.12%
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.29
Upside: +55.04%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $75.60
Upside: +5.82%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $6.76
Upside: +121.89%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $17.19
Upside: +161.78%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.42
Upside: +392.96%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $2.83
Upside: +182.69%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $1.11
Upside: +350.45%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $2.78
Upside: +295.68%